Hanbika Tablet 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hanpoong Pharmaceutical Co., Ltd.
MFDS item code 201906359 · Approved 2019.09.09
This product's status changed to Expired on 2024.09.09. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of Amlodipine or Olmesartan Medoxomil. This helps manage blood pressure appropriately, reducing the risk of cardiovascular complications and improving overall health.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted; however, if blood pressure is not controlled with monotherapy using the individual components, a direct switch to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in older adults.
∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; discontinuation should occur immediately upon confirmation of pregnancy. Patients with allergies to any ingredients in this medication or similar medications, or those who are pregnant or breastfeeding, patients with severely impaired liver or kidney function, and patients with certain heart diseases should not take this medication. Patients who are low in body fluids or sodium may experience hypotension when starting this medication; therefore, they should be monitored closely, and appropriate measures should be taken if hypotension occurs. Rapid dilation of blood vessels can lead to hypotension, so patients with certain heart conditions should exercise caution when taking this medication. Patients with weak heart function, impaired kidney function, or liver dysfunction should use this medication with special care. During the use of this medication, side effects like dizziness, headache, hypotension, gastrointestinal disturbances, rash, and edema may occur; consult with healthcare professionals if unusual symptoms arise. This medication may interact with other drugs, so if currently taking any other medications, it is essential to inform the healthcare professional, particularly when taking certain diuretics, antihypertensives, or potassium-sparing drugs. Pregnant women or those planning to become pregnant should avoid using this medication and discuss safer alternative treatments with their physician if necessary. Breastfeeding women are advised to either stop breastfeeding or discontinue this medication since it may be passed into breast milk. Children under 18 years of age should not take this medication since its safety and efficacy have not been established. Elderly patients should take this medication with caution as renal and liver function declines may increase drug concentrations; it is essential to adjust the dosage accordingly. In cases of overdose, symptoms like hypotension and tachycardia may occur; seek immediate medical treatment in such situations. This medication should be stored in a sealed container to prevent moisture and heat exposure, and should be kept out of reach of children; transferring to other containers should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air and moisture exposure. It is also advisable to store it at room temperature between 1 and 30 degrees Celsius.
Light yellow circular film-coated tablets
30 tablets/PTP [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hanpoong Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.